Evidence map›Paper›PMID 41941655›Full record

ArticleACS applied materials & interfaces2026

Probing Glycan-Gold Nanoparticle Architectures: Glycan Type, Density, and Linker Length, Governing Multivalent Lectin Binding and Viral Inhibition.

Maisie Holbrow-Wilshaw, Darshita Budhadev, Amy Madeleine Kempf, Inga Nehlmeier, Erin Tait, Stefan Pöhlmann, W Bruce Turnbull, Yuan Guo, Dennis McGonagle, Dejian Zhou

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maisie Holbrow-WilshawLeeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, Leeds LS2 9JT, United Kingdom.
Darshita BudhadevSchool of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.
Amy Madeleine KempfInfection Biology Unit, German Primate Center-Leibniz Institute for Primate Research, 37077 Göttingen, Germany.
Inga NehlmeierInfection Biology Unit, German Primate Center-Leibniz Institute for Primate Research, 37077 Göttingen, Germany.
Erin TaitSchool of Biomedical Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.
Stefan PöhlmannInfection Biology Unit, German Primate Center-Leibniz Institute for Primate Research, 37077 Göttingen, Germany.
W Bruce TurnbullSchool of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.ORCID 0000-0002-7352-0360
Yuan GuoSchool of Food Science and Nutrition and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.ORCID 0000-0003-4607-7356
Dennis McGonagleLeeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, Leeds LS2 9JT, United Kingdom.
Dejian ZhouSchool of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.ORCID 0000-0003-3314-9242

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multivalent lectin-glycan interactions (MLGIs) are widespread and vital for pathogen infection, cell-cell communication, and immune regulation, making them attractive therapeutic targets. Despite significant efforts, research progress in MLGI targeting therapeutics remains limited, due to our incomplete understanding of the structural and biophysical mechanisms of some key MLGIs, which has hampered the design of spatially matched multivalent therapeutics. Moreover, the overlapping glycan specificities of various lectins make it difficult to target MLGIs with high potency and selectivity. To address this challenge, we have recently developed polyvalent glycan nanoparticles (glycan-NPs) as biophysical probes for MLGIs. The NPs' unique, size-dependent optical properties are exploited as sensitive readouts for quantifying MLGI affinities and thermodynamics, while their nanoscale size and high electron microscopy contrast are exploited for probing binding modes and binding site orientation. Despite this success, how design features such as glycan type, density, and linker flexibility govern glycan-NP MLGI properties remains underexplored. In this work, we coated gold nanoparticles (GNPs) with varying densities of a lipoic acid-oligo(ethylene glycol)-α-manno-α-1,2-biose (DiMan) or fucose (Fuc) ligand of varying linker lengths and studied their MLGIs with DC-SIGN, an important tetrameric lectin viral receptor found on dendritic cells. Using our recently established GNP fluorescence quenching assay, we reveal that displaying DiMan or Fuc polyvalently on a GNP surface greatly enhances their DC-SIGN affinity, with low nanomolar apparent

Indexed as

Antiviral AgentsGoldLectinsMetal NanoparticlesPolysaccharidesCell Adhesion MoleculesDC-Specific ICAM-3 Grabbing NonintegrinHIV-1HumansLectins, C-TypeProtein BindingReceptors, Cell SurfaceThermodynamicsAntiviral AgentsCell Adhesion MoleculesDC-Specific ICAM-3 Grabbing NonintegrinGoldLectinsLectins, C-TypePolysaccharidesReceptors, Cell SurfaceDC-SIGNfluorescence quenchingglycoconjugategold nanoparticlemultivalent lectin−glycan interactionthermodynamicsviral inhibition

Identifiers

PMID41941655
PMCPMC13107371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.